[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645405":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":28,"locations":37,"responsibleParty":81,"collaborators":84,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":93,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":32,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":40,"whyStopped":32,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Komagome Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Foscenvivint","EXPERIMENTAL","Foscenvivint 280 mg\u002Fm2, once a week for 24 weeks",[13],"Drug: Foscenvivint",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg\u002Fm2, once a week for 24 weeks",[9],[20,21,22],"CBP-beta-catenin inhibitor","OP-724","PRI-724 (former name)",[24],{"name":25,"affiliation":26,"role":27},"Kiminori Kimura, MD","Tokyo Metropolitan Komagome Hospital","PRINCIPAL_INVESTIGATOR",[29,34],{"name":25,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","+81-3-3823-2101",null,"kiminori_kimura@tmhp.jp",{"name":35,"role":30,"phone":31,"phoneExt":32,"email":36},"Akemi Ikoma","akemi_ikoma@tmhp.jp",[38,58,73],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hokkaido University Hospital","RECRUITING","Sapporo","Hokkaido","060-8648","Japan","JP",{"type":47,"coordinates":48},"Point",[49,50],141.35,43.06667,{"lat":50,"lon":49},[53,57],{"name":54,"role":30,"phone":55,"phoneExt":32,"email":56},"Tomoyuki Endo, MD","+81-11-716-1161","t-endo@med.hokudai.ac.jp",{"name":54,"role":27,"phone":32,"phoneExt":32,"email":32},{"facility":59,"status":40,"city":60,"state":60,"zip":61,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"National Hospital Organization Osaka National Hospital","Osaka","540-0006",{"type":47,"coordinates":63},[64,65],135.50107,34.69379,{"lat":65,"lon":64},[68,72],{"name":69,"role":30,"phone":70,"phoneExt":32,"email":71},"Ryotaro Sakamori, MD","+81-6-6942-1331","sakamori@gh.med.osaka-u.ac.jp",{"name":69,"role":27,"phone":32,"phoneExt":32,"email":32},{"facility":26,"status":40,"city":74,"state":75,"zip":76,"country":44,"countryCode":45,"cosmosGeoPoint":32,"geoPoint":32,"contacts":77},"Bunkyo-Ku","Tokyo","113-8677",[78,79,80],{"name":25,"role":30,"phone":31,"phoneExt":32,"email":33},{"name":35,"role":30,"phone":31,"phoneExt":32,"email":36},{"name":25,"role":27,"phone":32,"phoneExt":32,"email":32},{"type":82,"investigatorFullName":25,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","Head, Department of Hepatology",[85,88],{"name":86,"class":87},"Japan Agency for Medical Research and Development","OTHER_GOV",{"name":89,"class":90},"Ohara Pharmaceutical Co., Ltd.","INDUSTRY","100645405","phase-2-a-phase-2-study-of-foscenvivint-in-liver-cirrhosis-patients-caused-by-hivhcv-co-infection-with-hemophilia-100645405",false,"NCT07681089","A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV\u002FHCV Co-infection With Hemophilia","A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV\u002FHCV Co-infection in the Setting of Hemophilia","OP-724-H202","Inclusion Criteria:\n\n* Patients with hemophilia and liver cirrhosis caused by HIV\u002FHCV co-infection who meet both of the following criteria:\n\n  1. Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at \\\u003C200 copies\u002FmL and a CD4-positive T lymphocyte count of ≥200 cells\u002FµL at screening.\n  2. Patients with HCV infection who have achieved sustained virologic response (SVR) at least 12 months before registration.\n\n     * Patients with Child-Pugh class A or B liver cirrhosis (Child-Pugh score 5-9).\n     * Patients who meet at least one of the following criteria for the diagnosis of liver cirrhosis:\n\n  \u003C!-- -->\n\n  1. Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening.\n  2. Abdominal CT showing changes in liver morphology and\u002For findings suggestive of portal hypertension.\n\n     * Patients with an Eastern Cooperative Oncology Group Performance Status of 0-2.\n\nExclusion Criteria:\n\n* Patients with liver cirrhosis caused by etiologies other than HCV or of unknown etiology.\n* Patients with esophageal or gastric varices judged by endoscopic examination at screening to require treatment.\n* Patients with current malignancy or a history of malignancy within 3 years before registration.\n* Patients who have undergone liver transplantation or other organ transplantation, including bone marrow transplantation.\n* Patients with active AIDS-defining disease requiring treatment. -","MALE","18 Years","79 Years",{"count":103,"type":104},4,"ESTIMATED","INTERVENTIONAL",[107],"PHASE2","This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV\u002FHCV co-infection in the setting of hemophilia.",[110],"Liver Cirrhosis",[110,112,113],"Hemophilia","HIV\u002FHCV co-infection","2026-08-03",{"date":116,"type":117},"2026-08-05","ACTUAL",{"date":119,"type":104},"2026-09-01",{"date":121,"type":104},"2028-03-31",{"name":25,"class":6},3]